Opioid Drugs Market: Global Industry Size, Share, Growth, Trends, Analysis, and Forecast 2017 To 2025 | Credence Research

Opioid Drugs Market: Global Industry Size, Share, Growth, Trends, Analysis, and Forecast 2017 To 2025 | Credence Research

Credence Research
“Opioid Drugs Market (Drug Type: Opioid Agonist (Morphine, Methadone, Codeine, Oxycodone, Meperidine, Fentanyl and Other Agonist), Opioid Antagonist (Naloxone, Naltrexone and Other Antagonist); Application Type: Pain Management, Cough Suppressant, Diarrhea and Anesthesia)) – Growth, Future Prospects and Competitive Analysis, 2017-2025,”

As per the current report published by Credence Research, Inc. “Opioid Drugs Market (Drug Type: Opioid Agonist (Morphine, Methadone, Codeine, Oxycodone, Meperidine, Fentanyl and Other Agonist), Opioid Antagonist (Naloxone, Naltrexone and Other Antagonist); Application Type: Pain Management, Cough Suppressant, Diarrhea and Anesthesia)) – Growth, Future Prospects and Competitive Analysis, 2017-2025,” the global opioid drugs market was estimated at US$ 33.68 Bn in 2016 and is predicted to grow at CAGR of 4.4%.

Market Insights:

Opioids is a promising pharmaceutical drug class with major application in pain management. Opioid drugs help to alleviate pain by binding with opioid receptors present on the nervous system. Opioid drugs not only exhibit promising effect in relieving pain, suppressing cough and as an anesthetic agent, but also in treating diarrhea, opioid usage disorders and to reverse the opioid overdose effects. However, side effects associated with opioid drugs, opioid abuse and addiction have affected overall opioid drugs market.

Browse the full report Opioid Drugs Market – Growth, Future Prospects and Competitive Analysis, 2017–2025 report at https://www.credenceresearch.com/report/opioid-drugs-market

Opioids have huge medical application in treating pain associated with cancer, AIDS and arthritis; globally increasing prevalence of these diseases promote the growth of opioid drugs market. Rising trend of surgical interventions subsequently increase the usage of opioid drugs both in treating surgical pain and as anesthetic agents. Although, expanding opioid abuse and addiction have led to unethical sales of opioid drugs; serious health issues caused by opioid overdose and addiction have drawn the attention of healthcare administration. As a result, the stringent regulatory guidelines on opioid usage is expected to hinder the swift growth of the opioid drugs market. Recently, the FDA has ordered Endo Pharmaceuticals to withdraw the long lasting opioid drug Opana ER from the market. Such strict regulations are expected in the near future, because of public health concern.

Some latest approved opioid drugs are Arymo ER and Vantrela and RoxyBond being commercialized as the first and only immediate-release opioid analgesic claimed to have abuse-deterrent label. Such increasing trend of approval of safer drugs and robust pipeline portfolio is presumed to promote continuous growth to the market. Furthermore, market infiltration of non-opioid drugs outweigh the preference for opioid drugs due to increasing rate of reported cases of opioid overdose deaths.

Based on different types of opioid drugs, the market is segmented into morphine, methadone, codeine, oxycodone, meperidine, and fentanyl. Morphine and codeine collectively are boosting the overall growth of opioid drugs market as a result of effective outcomes in pain management and cough suppression. On the basis of applications of opioid drugs, the pain management segment is estimated to generate maximum revenue due to increasing prevalence of chronic pain, which is the leading cause of physical disability worldwide.

Geography wise, the global opioid drugs market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. With respect to the present scenario, North America is the dominating region in global opioid drugs market owing to increasing prevalence of cancer and chronic pain. Maximum consumption of prescribed and over-the-counter opioid drugs and growing epidemic of opioid addiction made North America the leading regional market followed by Europe. Asia Pacific is expected to experience major growth due to booming market in China and emerging healthcare development.

The key business players in opioid drugs market include Actavis Plc., Boehringer Ingelheim, Endo Pharmaceuticals Inc., Egalet, Janssen Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Pfizer Inc., Purdue Pharma, Sanofi, Sun Pharmaceutical Industries Ltd.

Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/58852

Table of Content

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Opioid Drugs Market Portraiture
2.1.1. Global Opioid Drugs Market, by Drug Type, 2016 (US$ Mn)
2.1.2. Global Opioid Drugs Market, by Application, 2016 (US$ Mn)
2.1.3. Global Opioid Drugs Market, by Geography, 2016 Vs. 2025 (Value %)

Chapter 3. Opioid Drugs Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Opioid Drugs: Future Trends
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2016
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Opioid Drugs Market, by Drug Type, 2015 – 2025 (US$ Mn)
4.1. Overview
4.1.1. Attractive Investment Proposition: Global Opioid Drugs Market, by Drug Type, 2016
4.2. Morphine
4.3. Methadone
4.4. Codeine
4.5. Oxycodone
4.6. Meperidine
4.7. Fentanyl
4.8. Others

Chapter 5. Global Opioid Drugs Market, by Application, 2015 – 2025 (US$ Mn)
5.1. Overview
5.1.1. Attractive Investment Proposition: Global Opioid Drugs Market, by Application, 2016
5.2. Pain Management
5.3. Cough Suppressant
5.4. Diarrhea 
5.5. Anesthesia

Chapter 6. Global Erectile Dysfunction Treatment Drugs Market: Pipeline Analysis
6.1. Overview
6.2. Phase III (Market estimations by 2025)
6.2.1. NKTR 181 (Nektar Therapeutics)
6.3. Phase II (Qualitative Information)
6.4. Phase I (Qualitative Information)
6.5. Preclinical Studies (Quantitative Information)

Chapter 7. Global Opioid Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
7.1. Overview
7.2. North America Opioid Drugs Market Analysis, 2015 – 2025 
7.2.1. North America Opioid Drugs Market, by Drug Type, 2015 – 2025 (US$ Mn)
7.2.2. North America Opioid Drugs Market, by Application, 2015 – 2025 (US$ Mn)
7.2.3. North America Opioid Drugs Market, by Country, 2015 – 2025 (US$ Mn)
7.2.3.1. U.S.
7.2.3.2. Canada
7.3. Europe Opioid Drugs Market Analysis, 2015 – 2025 
7.3.1. Europe Opioid Drugs Market, by Drug Type, 2015 – 2025 (US$ Mn)
7.3.2. Europe Opioid Drugs Market, by Application, 2015 – 2025 (US$ Mn)
7.3.3. Europe Opioid Drugs Market, by Country, 2015 – 2025 (US$ Mn)
7.3.3.1. U.K.
7.3.3.2. Germany
7.3.3.3. Rest of Europe
7.4. Asia Pacific Opioid Drugs Market Analysis, 2015 – 2025 
7.4.1. Asia Pacific Opioid Drugs Market, by Drug Type, 2015 – 2025 (US$ Mn)
7.4.2. Asia Pacific Opioid Drugs Market, by Application, 2015 – 2025 (US$ Mn)
7.4.3. Asia Pacific Opioid Drugs Market, by Country, 2015 – 2025 (US$ Mn)
7.4.3.1. Japan
7.4.3.2. China
7.4.3.3. India
7.4.3.4. Rest of APAC
7.5. Latin America Opioid Drugs Market Analysis, 2015 – 2025 
7.5.1. Latin America Opioid Drugs Market, by Drug Type, 2015 – 2025 (US$ Mn)
7.5.2. Latin America Opioid Drugs Market, by Application, 2015 – 2025 (US$ Mn)
7.5.3. Latin America Opioid Drugs Market, by Country, 2015 – 2025 (US$ Mn)
7.5.3.1. Brazil
7.5.3.2. Mexico
7.5.3.3. Rest of Latin America
7.6. Middle East & Africa (MEA) Opioid Drugs Market Analysis, 2015 – 2025 
7.6.1. MEA Opioid Drugs Market, by Drug Type, 2015 – 2025 (US$ Mn)
7.6.2. MEA Opioid Drugs Market, by Application, 2015 – 2025 (US$ Mn)
7.6.3. MEA Opioid Drugs Market, by Country, 2015 – 2025 (US$ Mn)
7.6.3.1. GCC
7.6.3.2. South Africa
7.6.3.3. Rest of MEA

Chapter 8. Company Profiles
8.1. Actavis Plc.
8.1.1. Business Description
8.1.2. Financial Information (Subject to data availability)
8.1.3. Product Portfolio
8.1.4. Key Developments
8.2. Boehringer Ingelheim
8.3. Endo Pharmaceuticals Inc.
8.4. Egalet 
8.5. Janssen Pharmaceuticals, Inc.
8.6. Mallinckrodt Pharmaceuticals
8.7. Pfizer Inc.
8.8. Purdue Pharma 
8.9. Sanofi
8.10. Sun Pharmaceutical Industries Ltd.

Do Inquiry before buying for research report: https://www.credenceresearch.com/inquiry-before-buying/58852

Our Blog: http://tcnindustry.com/

Media Contact
Company Name: Credence Research
Contact Person: Chris Smith, Global Sales Manager
Email: Send Email
Phone: +1-800-361-8290
Address:105 N 1st ST #429, SAN JOSE, CA 95103 US
City: SAN JOSE
State: California
Country: United States
Website: http://www.credenceresearch.com/report/artificial-lift-system-market